大参林（603233）：Q3业绩高速增长，经营质量持续提升

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the benchmark index within the next six months [10][16]. Core Insights - The company has demonstrated strong performance in Q3 2025, with a year-to-date revenue of 20.068 billion yuan, reflecting a 1.71% increase, and a net profit attributable to shareholders of 1.081 billion yuan, up 25.97% [4]. - The retail business has shown improvement in gross margin, with a gross margin of 37.70%, up 0.44 percentage points year-on-year, driven by effective promotional strategies and supply chain optimization [5]. - The company is expanding its store network dynamically, with a total of 17,385 stores as of September 30, 2025, including 7,029 franchise stores, and has closed 447 direct-operated stores [7]. Financial Performance - For Q1-Q3 2025, the company reported a gross margin of 34.82%, a net profit margin of 5.39%, and a non-recurring net profit margin of 5.35% [5]. - Revenue from the retail business was 16.340 billion yuan, while the franchise and distribution business generated 3.199 billion yuan, marking an 8.38% increase [5][6]. - The company expects revenues of 29.150 billion, 32.106 billion, and 35.434 billion yuan for 2025, 2026, and 2027 respectively, with net profits projected at 1.147 billion, 1.320 billion, and 1.522 billion yuan [8][10]. Market Position - The company is positioned well within the pharmaceutical retail sector, with stable demand for its products, particularly in traditional Chinese medicine and Western medicine [6]. - The company has effectively utilized its franchise model to expand its market presence in less competitive regions, contributing to revenue growth in the franchise and distribution segment [5]. Valuation Metrics - The current price-to-earnings (P/E) ratio is 21.53, with projected P/E ratios of 17, 15, and 13 for the years 2025, 2026, and 2027 respectively [3][10]. - The company’s asset-liability ratio stands at 69.2%, indicating a relatively high level of leverage [3].